An improved clinical model to predict stimulated C-peptide in children with recent-onset type 1 diabetes.
Kerry Buchanan, Ahmed M Mehdi, Ian Hughes, Andrew Cotterill, Kim-Anh Le Cao, Ranjeny Thomas, Mark Harris
Pediatr Diabetes | Published : 2019
BACKGROUND: Stimulated C-peptide measurement after a mixed meal tolerance test (MMTT) is the accepted gold standard for assessing residual beta-cell function in type 1 diabetes (T1D); however, this approach is impractical outside of clinical trials. OBJECTIVE: To develop an improved estimate of residual beta-cell function in children with T1D using commonly measured clinical variables. SUBJECTS/METHODS: A clinical model to predict 90-minute MMTT stimulated C-peptide in children with recent-onset T1D was developed from the combined AbATE, START, and TIDAL placebo subjects (n = 46) 6 months post-recruitment using multiple linear regression. This model was then validated in a clinical cohort (H..View full abstract
Awarded by Juvenile Diabetes Research Foundation
Awarded by National Health and Medical Research Council